EUCTR2011-000083-10-DE进行中（未招募）1 期
An Open-Label, Randomized, Multicenter Phase 2 Trial of Dasatinib (SPRYCEL®) vs. Dasatinib plus Smoothen Antagonist (BMS-833923) in the Treatment of Subjects with Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CMLPharmacogenetics Blood Sample Amendment 01 - site specific (v1.0,dated 30-Mar-2011)Protocol Amendment 03 - Country Specific - Germany Only (v1.0, dated 22-Jun-11)
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subjects >= 18 years of age who have signed informed consent
- •2. Philadelphia positive chronic myeloid leukemia (CML) in chronic phase
- •3. Previously untreated
- •4. Performance status 0 - 2
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 270
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •1. Known Abl-kinase T315I or T315A mutation
- •2. Serious or uncontrolled medical disorder (including infection or cardiovascular disease) or dementia or other serious psychiatric condition
- •3. Prior chemotherapy
- •4. Women who are pregnant or breastfeeding or WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy during the entire study period
研究者
相似试验
进行中（未招募）
不适用
PH II DASATINIB COMBO w/ SMO INHIBITOR (BMS-833923)EUCTR2011-000083-10-FIBristol-Myers Squibb International Corporation300
进行中（未招募）
不适用
PH II DASATINIB COMBO w/ SMO INHIBITOR (BMS-833923)EUCTR2011-000083-10-BEBristol-Myers Squibb International Corporation300
进行中（未招募）
1 期
PH II DASATINIB COMBO w/ SMO INHIBITOR (BMS-833923)newly diagnosed Ph+ CP CMLMedDRA version: 14.0Level: LLTClassification code 10054352Term: Chronic phase chronic myeloid leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10034877Term: Philadelphia chromosome positiveSystem Organ Class: 10022891 - InvestigationsEUCTR2011-000083-10-ESBristol-Myers Squibb International Corporation70
进行中（未招募）
不适用
Randomized, Open-Label, Multicenter Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers.Advanced or Metastatic Non-squamous Non Small Cell Lung Cancer (NSCLC)MedDRA version: 17.1Level: LLTClassification code 10029514Term: Non-small cell lung cancer NOSSystem Organ Class: 100000004864EUCTR2014-002565-30-FRAbbVie Deutschland GmbH & Co. KG525
进行中（未招募）
1 期
Randomized, Open-Label, Multicenter Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers.Advanced or Metastatic Non-squamous Non Small Cell Lung Cancer (NSCLC)MedDRA version: 19.0 Level: LLT Classification code 10029514 Term: Non-small cell lung cancer NOS System Organ Class: 100000004864EUCTR2014-002565-30-CZAbbVie Deutschland GmbH & Co. KG525